INNV - NASDAQ

Thank you for standing by. Welcome to InnovAge First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ryan Kubota, Director of Investor Relations. Please go ahead.

Thank you, operator. Good afternoon, and thank you all for joining the InnovAge fiscal 2024 First Quarter Earnings Call. With me today is Patrick Blair, President and CEO; Benjamin Adams, CFO; Dr. Rich Feifer, our Chief Medical Officer, will also be joining the Q&A portion of the call. Today, after the market closed, we issued a press release containing detailed information on our quarterly results. You may access the release on our company website, innovate.com. For those listening to the rebroadcast of this call, we remind you that the remarks made herein are as of today, Tuesday, November 7, 2023, and have not been updated subsequent to this call. During our call, we will refer to certain non-GAAP measures. A reconciliation of these measures to the most directly comparable GAAP measures can be found in our fiscal first quarter 2024 earnings release, which is posted on the Investor Relations section of our website. We will also be making forward-looking statements, including statements related to our future growth prospects, Florida de novo centers, potential acquisitions, our payer capabilities and clinical value initiatives, the status of current and future regulatory actions and other expectations. Listeners are cautioned that all of our forward-looking statements involve certain assumptions and are inherently subject to risks and uncertainties that can cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our Form 10-K annual report for fiscal year 2023 and our subsequent reports filed with the SEC, including our quarterly report on Form 10-Q for our fiscal first quarter 2024. After the completion of our prepared remarks, we will open the call for questions. I will now turn the call over to our President and CEO, Patrick Blair.

Thank you, Ryan, and good afternoon, everyone. I want to begin by expressing my ongoing gratitude to our InnovAge colleagues, participants, government partners and the investor communities for the organization. As it's only been 2 months since we reported fiscal year '23 results on September 12. My remarks will be brief and hit on our results for the first quarter of fiscal year 2024 and progress in our key focus areas. The company's first quarter results were in line with our expectations and reflect continued momentum in our people, service, quality, growth and financial performance measures. Our progress in these areas gives us confidence that we're growing our business in a financially responsible way, delivering high-quality service to our participants, all while ensuring their employees are engaged and committed to our mission. I'll spend more time on these areas in a moment. We reported revenue of $182.5 million, an increase of approximately 3.2% compared to the fourth quarter of fiscal year '23 and center level contribution margin of $27.9 million, which represents a 15.3% margin. Adjusted EBITDA was $2.2 million for the quarter, which represents a significant improvement compared to the fourth quarter of fiscal year 2023, which was approximately $700,000. Census increased to 6,580 which represents a quarter-over-quarter improvement of 2.8%. The results represent continued sequential improvement, and we remain convinced that we have the capacity to deliver even more value to our federal, state and shareholder partners over time. We have the right team in place, and we continue to build and enhance our processes and technology. It now boils down to driving consistent execution. That said, we're still in the early innings, post-sanctions, and on the path back to unlocking the full potential of the organization. We remain focused on growing into the stock capacity at our existing centers, which is creating operating leverage in enabling contribution margin improvement through incremental enrollments until we reach targeted staffing ratios, particularly in the Colorado market, enrollment growth is driving better center labor utilization, and this is also helping rebalance our mix of new and tenured participants, which should improve participant PMPM expense over time. While we remain steadfast and are sissy, it will take us time to achieve the full impact forwarders. For example, while overall external provider costs were modestly higher than fourth quarter of fiscal year 2023, we observed positive trends within the quarter, which indicates the clinical value initiatives we launched in early late last year are starting to impact our medical costs. As we noted in our last call, we expect improvement in our medical costs throughout the fiscal year as our initiatives mature and growth positively impacts our participant mix. Turning back to our performance across people, service, quality, growth and financial measures. We've just concluded our quarterly reporting for employee engagement, our people measure, participant in Net Promoter Score or NPS or service measure and clinical quality. Our employee engagement score increased by 5% to 77%, reflecting increases in 12 of our centers. Our participant NPS increased by 13 points to 47%, reflecting improvement in 15 of our centers. And based on the NPS methodology, we believe our score positions us comparatively among the top tier of health care organizations. From a quality perspective, we're seeing solid results in inpatient utilization, fall rates and cognitive screens, among others, and we believe our results reflect top-tier performance and on PACE organizations. It's our strong belief that we have highly engaged employees, delivering great service and quality, growth and financial performance will follow. I'll now spend a few minutes walking through our key focus areas. Starting with existing center growth, new participant monthly gross enrollment is back to pre-sanction levels. We enrolled over 200 participants across all of our centers in both August and September, which is consistent with the company's best presanction periods. Specifically, the enrollment ramp in our previously sanctioned markets continues to gain momentum as Sacramento was now at presanction levels, and Colorado has seen monthly sequential improvement over the last 6 months. Further, our East region gross enrollments were up 33% for the first quarter of fiscal year '24 compared to the first quarter of fiscal year '23. Contributing to our post-sanction enrollment ramp is the success of our new digital marketing initiatives. We've seen first quarter sales qualified leads increased by approximately 75% year-over-year, which gives us increasing confidence that our marketing messages are reaching our target audiences, and there is strong interest in our value proposition from underserved seniors, looking for services and support to help them stay simply in their homes as they age. Given the increased digital lead volume, we've made a modest investment in an inside sales team that has worked in the digital leads, which allows our field enrollment teams to remain focused on self-generated needs from our community referral partners. While it's still early days for the inside sales capability, we're optimistic about the impact on growth, field enrollment productivity and reducing participant acquisition costs. You'll recall last quarter, we touched on enrollment as a joint effort between innovation and our state partners and the state subcontractors who may perform assessments, validate our assessments and ultimately process the applications and activate new enrollments. We continue to observe situational delays in some markets in the processing of enrollment applications, and we primarily attribute this to state resource insurance. While this doesn't impact the eligibility of our prospective participants, it can delay enrollments and cause eligible participants to seek other solutions. We are working collaboratively with all the stakeholders for which we have some dependency to address delays proactively as they surface to ensure we can enroll deserving seniors as quickly as possible. I'd like to take a moment to thank our partners for their ongoing support and collaboration as we work together to help more seniors benefit from PACE. In Florida, we continue to make progress on the administrative requirements to open centers in Tampa and Orlando. We recently moved to the next stage of the process at Tampa, which is the final review by CMS. In Orlando, we conducted the state readiness review in October and anticipate feedback imminently. You'll recall from last quarter's update, that we're targeting opening around the end of the calendar year. While we are doing everything in our control to open these centers as quickly as we can. Now all the steps are in our locus of control, and it is becoming increasingly likely that opening dates for Tampon Orlando could shift to early in the new year. Overall, we remain enthusiastic that these 2 centers will expand our total center and census capacity by over 20% and believe each center with sites capacity of 1,300 will meaningfully increase our overall organic growth curve over the next couple of years. Regarding our de novo Syntron in California, a large market, Southeast of Los Angeles, we continue to work with the Department of Health care services in California toward a midyear calendar 2024 opening. We're excited to get these new centers up and running and serving the communities. In addition to same-center organic growth, we believe these new locations create visibility into multiyear double-digit top line growth and embedded future earnings. Operationally, we continue to make meaningful progress improving how we're managing our centers according to what we call the One Innovate way. We're reducing variation in business processes, policies and procedures among our centers, which is leading to improvements in operational clients, productivity, clinical quality and unit economics across our platform. Clinically, we continue to strengthen our payer capabilities through our clinical value initiatives. This quarter, we achieved meaningful improvements in inpatient utilization, which was 5.3% relative to 5.8% in the fourth quarter of fiscal year '23. We've kept our short-stay skilled nursing utilization rate below 2% this quarter, which you'll recall was down approximately 23% in fiscal year '23 relative to fiscal year 2022. And we've begun transitioning our assisted living facility in nursing home providers into high-performing networks, which include providers who consistently deliver more compliant and higher quality care, lower cost and are more collaborative with our care teams. We're excited about the impact this will have on the quality of care we can offer our participants. Further, we continue to work with our vendors to identify improvements in risk for capture accuracy. Counterbalancing the improvements in utilization that we're seeing, we have observed some modest increase in inpatient unit cost and higher outpatient services utilization in the first quarter, which isn't unexpected as we continue to work through the wondering risk pool impacts of the Colorado station on participant acuity. We continue to work through the multiple levers to get to targeted levels and ensure a financially attractive margin overall. Regarding technology, we have 14 of our 17 centers live on Epic, with the remainder scheduled for the second fiscal quarter. Though it takes time to realize the full extent of anticipated benefits of our new system, we're encouraged by the operational efficiencies that are emerging in the positive feedback our administrative and clinical teams are sharing. For example, since going live in Pennsylvania, Virginia and Colorado, we have exchanged over 200,000 participant health records with specialists and hospital partners using Epic's interoperability capability within their provider ecosystem. Previously, this level of health information exchange consumes significant labor and time and was prone to inefficiency and rework. Now we have a single record source, which is shared and available real time with many of our external partners. We expect that in time, the network effect will grow, and it will enable better service, access, quality, cost and labor efficiency. Further, Epic ranks its users against the overall Epic community as our clinicians go live and features are implemented. As a testament to our early progress, Epic has shared with us that we're in the top quartile of feature adoption in the areas of physician productivity, nurse productivity and population health intent. As I've mentioned, these are all dials and not switches, but we're pleased to see these activities starting to have an impact and ultimately value in our business. In summary, we're just beginning to unlock the full potential of the organization. I greatly appreciate the continued commitment from our more than 2,100 colleagues nationally and the ongoing support of our valued government partners. We remain focused on demonstrating incremental improvement quarter-over-quarter in each of our focus areas. I believe there is momentum building from our team's work. And in time, this will translate to improved financial performance and enable us to return to normalized margins. We are humbled by the responsibility to serve the many underserved pay cells in our communities and are thrilled to be returning to responsible growth. With that, I'll turn it over to Ben to review the financials in detail.

Thank you, Patrick. Today, I will provide some highlights from our first quarter fiscal year 2024 financial performance compared to the fourth quarter as well as provide insight into some of the trends we are seeing evident to the winter months of the year. While it's still early in the fiscal year, we continue to track and make progress on the guidance targets we provided on our fourth quarter earnings call. Starting with Census, we ended the first quarter of fiscal year 2024 with 17 centers and approximately 6,580 participants as of September 30, 2023. This represents an ending census increase of 2.8% compared to last quarter. We reported approximately 19,540 member months in the first quarter of fiscal year 2024, a 2.3% increase compared to the fourth quarter. Total revenue increased by 3.2% to $182.5 million in the first quarter compared to the fourth quarter, primarily due to an increase in member months coupled with an increase in capitation rates associated with annual Medicaid rate increases effective July 1, and partially offset by favorable Medicare risk or true-ups recorded in the fourth quarter. We incurred $99.4 million of external provider costs during the first quarter of fiscal 2024, a 4.6% increase compared to the fourth quarter. The sequential increase was driven by an increase in member months as we continue to grow Census coupled with an increase in cost per participant. The cost per participant increase was driven by higher assisted living and nursing facility unit costs as a result of annual provider increases, higher cost per admission due to acuity and an increase in pharmacy expense. These costs were partially offset by reductions in permanent and short-stay nursing facility utilization and a reduction in inpatient utilization. Cost of care, excluding depreciation and amortization of $55.3 million was 3.5% higher compared to the fourth quarter. Primary cost drivers include salaries, wages and benefits primarily associated with annual merit increases and an increase in fleet and contract transportation utilization as a result of census growth, higher fuel costs, vehicle repairs and maintenance. These costs were partially offset by a reduction in third-party audit remediation and consulting costs. Central level contribution margin, which we define as total revenue less external provider costs and cost of care, excluding depreciation and amortization, was $27.9 million for the quarter compared to $28.5 million in the fourth quarter. As a percentage of revenue, center level contribution margin was 15.3% compared to 16.1% in the fourth quarter. Sales and marketing expense was $5.4 million, a $750,000 decrease compared to the prior quarter. The decrease was mainly due to lower marketing spend as we focused on our digital channels in the first quarter ahead of a new marketing campaign that we launched this month. Corporate, general and administrative expense declined slightly to $28.9 million, a $50,000 decrease compared to the fourth quarter. Net loss was $11 million compared to a net loss of $12 million in the fourth quarter. We reported a net loss per share of $0.08 on both a basic and diluted basis. And our weighted average share count was approximately 135.8 million shares for the quarter on both a basic and fully diluted basis. Adjusted EBITDA, which we calculate by adding interest, taxes, depreciation and amortization, de novo losses and other nonrecurring or exceptional cost to net loss, was $2.2 million for the quarter compared to $700,000 in the fourth quarter. Our adjusted EBITDA margin was 1.2% for the fiscal year compared to 0.4% in the fourth quarter. Adjusted EBITDA of $2.2 million is inclusive of de novo losses, which was $1.6 million for the first quarter and primarily related to our centers in Florida. This compares to $1.5 million of de novo losses in the fourth quarter. Turning to our balance sheet, we ended the quarter with $88.4 million in cash and cash equivalents, plus $46.8 million in short-term investments. We had $85.5 million in total debt on the balance sheet, representing debt under our senior secured term loan plus finance lease obligations and other commitments. For the first quarter, we recorded negative cash flow from operations of $33.6 million, inclusive of approximately $15 million in delayed payments from California that we received in October and we had $2.6 million of capital expenditures. Finally, I will briefly touch on some of the trends that are developing as we head into the winter months. Regarding Census, our census growth is tracking in line with our guidance expectations. As Patrick mentioned, we continue to expect that states will have short-term constraints around their ability to process new enrollments as they prioritize their needs to process Medicaid redeterminations along with their other obligations. However, we are not seeing that impact our Census in a meaningful way. Regarding revenue and rates, we have yet to finalize Medicaid rates in New Mexico and remain in active discussions with the state for fiscal year 2024. In California, we have started the annual rate process with the state, and we expect to know more about the state's timing in the coming weeks. Regarding cost trends, as we head into the winter months, it is important to remember that we typically see an increase in external provider costs as a result of seasonality. Specifically, we expect to see higher inpatient and short-stay nursing home utilization as well as increased acuity of our participant mix. In closing, we continue to focus on improving the margin profile of the business by concentrating on the key drivers we highlighted last quarter. Accelerating census growth, which also serves to rebalance the participant risk pool as well as unlock staffing capacity, ensuring our participant risk scores are commensurate with our risk pool through improved participant data management as we fully implement Epic, optimizing revenue per participant through proactive actuarial discussions with our state Medicaid agencies and executing on clinical value initiatives to improve participant care and reduce unnecessary costs. We hope to share more information on these key initiatives on our next call. Operator, that concludes our prepared remarks. Please open the call for questions.

Thank you. [Operator Instructions] Our first question comes from the line of Jamie Perse with Goldman Sachs.

I wanted to start with just some of the comments on enrollment trends and just your level of confidence in the guidance that you laid out so far and your progress this year. Maybe comment on the headwind you're experiencing in terms of enrollment, how much that impacts guidance for the year? And then also just the Florida delay and potential opening of those centers in the early part of next calendar year. How much was contemplated in guidance with respect to that? And should we be thinking about that as a headwind relative to your prior guidance?

Well, thanks, Jamie. I'll get to start and then hand it over to Ben. In terms of just our confidence levels and momentum around enrollment and we're feeling very good about the progress we're making across all of our markets. We're pushing ourselves every month on this every month, I'm pushing the team to find some new way to accelerate our growth. And I think the team is doing a great job. I think in my prepared remarks, I talked a bit about the inside sales capability, which is a new capability that we're seeing is some early indicators that it's going to have an impact. And I think there's still incremental opportunities out there to become more efficient, more productive, but when we look at Colorado or Sacramento, some of the new markets that are coming online, we're feeling really positive about the momentum that the team is building. And in our markets that have been online for a while, we're achieving some better growth rates than we have in the past. So overall, feeling really good about that. In terms of the headwinds, I think you're referring to just comments related to the processing of enrollments. And we pointed that out a couple of times. I think last quarter was the first time we raised that. Really, as I said in the remarks, it's really situational. It's not happening in every market. We're working through each of those issues with those states. At this point, we're not concerned that as a wider scale issue that we have to be concerned with the team is just doing a good job. It's just one of those things that I think it's the first time we've really seen resource constraints in some of our markets as it relates to processing enrollments. And we know both our states and CMS have a lot on their plate as it relates to redetermination. So I think those are some of the highlights on existing growth. I'll pass it over to Ben out here to hit Florida and sort of how to think about guidance.

Yes. I mean I think Patrick actually captured most of it there. The one thing I'd say is if you take a look at the growth that we had in the first quarter, both in terms of census and member months and then begin to annualize out those rates, you sort of end up at a place that makes you feel pretty comfortable with that guidance. And if you also look at what's happening, I think, in the enrollments over the last couple of months, it feels like we're building momentum on the enrollment slightly on a month-over-month basis. So I think you sort of factor those things 2 things together, and you feel like we're pretty confident we're going to end up right in the guidance range.

My next question is just the external provider costs. Those were a little bit higher than we expected. It sounds like some of that was in Colorado and just the shift in acuity there, the mix of patients. Can you talk a little bit more about what you're seeing in the inpatient and outpatient utilization trends? And then I guess, just any comments on how to think about the cadence. It sounds like you typically see a step-up in the calendar fourth quarter, your second quarter just around flu and all the dynamics that go with that and as well as COVID. So maybe just any comments to frame what we should think about for the step-up in external provider cost sequentially?

Jimmy. Again, I'll kind of get us started, and then I'll hand it off to Dr. Feifer to put a finer point on it. When I think about from a participant expense perspective, maybe what's not going exactly to plan. And it's really a couple of hotspots around yard emissions. We've always done a great job managing ER admissions, and we saw a little bit of a tick up relative to historical trends and so we've got a number of initiatives lined up against that. I think we have 11 or 12 initiatives that really focus on making sure people call us before they go to an emergency room. And I feel confident in the work that Rich and team are doing. So I think that's one that hopefully just kind of falls back in the line. The second area is around inpatient unit costs. As we noted, we're seeing some improvements in inpatient utilization, and I think maybe that's a variance with what some of the other payers might be reporting. For us, it's probably, hypothesis makes more acuity but on the unit cost side. And so we're digging into that, trying to answer why that's happening, but I'll let Rich just go a little bit deeper on each of those. And then your point about seasonality, it will play a role given how frail our population is for sure, whether that be flu or COVID. So it will be a perfect straight line quarter-by-quarter of the drop in the anticipated, I should say, the anticipated improvements in medical costs. But we think we're doing all the right things. We've got a lot of great initiatives that are underway, and it just takes a while for them to flow through sort of the cost structure. And as you know, at this point, we're really in complete a lot of the claims history. So there's a lot of estimates still in our numbers, and we'll just let those things play through as well. But overall, I'm really feeling good about the team and what they're focused on. But let me ask Rich to hit his fire points on each of those.

Great. Thanks, Patrick. Let me pick up where you left off on the second question about respiratory illness and seasonality. We are already seeing an uptick in respiratory illness, but we are not seeing that translate into higher inpatient utilization at this point. Although we do anticipate that to some extent, and we budget for it. We are working really hard to maximize influenza and COVID vaccination rates to protect our population. We are seeing more COVID just as everyone is seeing in the community, but so far, most of those cases are actually mild even in our vulnerable population. Back to the point about outpatient utilization, as Patrick said, we are seeing very effective reductions through a lot of the interventions of our team reductions in inpatient utilization. And in some ways, that's leaving those who are ultimately admitted to be more severely afflicted and have higher unit costs because they are the ones who really need to be admitted. So in some ways, it shouldn't be surprising to us that we're seeing some increase in severity or acuity in addition to the aging of our population, but we're working on that very closely to ensure that there are things that we could mitigate whether they be rates or steerage to lower-cost providers. I'd also echo Patrick's point around ER diversion because we are seeing increases in ER utilization, which are going in the other direction from inpatient. Part of that relates to our facility partners, assisted living facilities and nursing homes and to Patrick's point earlier around moving to a high-performance network part of our definition of a high-performance network going forward will be how well those facilities work with us when there's a minor change of conditions so that we can address that change of condition without utilizing the emergency so it's a key intervention going forward.

[Operator Instructions] Our next question comes from the line of Matt Larew with William Blair.

This is actually Madeline on for Matt. Kind of following up on the patient acuity question. I know one of the things that you are anticipating once sort of the sanctions were lifted, was that the pace and acuity mix would normalize a little bit because you were able to enroll new patients. Can you talk a little bit about like what you're seeing in terms of new enrollee patient acuity and how that mix might have changed now that you've had a couple of months of being able to enroll patients?

Sure. I'll start again and have Rich filling gaps. The first thing I would say is that the sort of the mix issue is obviously very dependent on the rate of growth of our new enrollment and the progression of our existing patient base and discipline, frankly, that's attributable to death. So all those factors come kind of play into the risk pool changing. What I would say is, if I think about the mix of new participants, again, still early because it's there was a bit of a ramp in Colorado, in particular. But I think one of the things we're starting to see is fewer people enrolling with us that are in an assisted living facility. Pace is a great solution for people, and that's an important lever for us to avoid nursing facility care. And I think historically, we maybe saw a little bit higher levels assisted living facility enrollments. I think we're starting to see some of that, let's call it, backlog, pent-up demand, maybe starting to play through. So our mix is increasingly looking more and more what we would expect a community mix to look like between people in nursing homes, people in assisted living and people who are coming to us living independently. So still early, but seeing some good signs that, again, the work that Rich is leading is having an impact. And our high-performing network is another great example of making sure we're providing all the access that's necessary for this.

Well, yes, exactly, as Patrick said, we are seeing lower acuity people being enrolled than our existing population by definition because these are people who are living either independently or in assisted living. Now we have had and seen a backlog of interested people, people wanting to enroll an innovate pace who were living in assisted living in Colorado. And as that backlog work to sell out, we're seeing much higher rates of true independent living, and so our acuity and our mix will become even more favorable over time.

Got it. That's really helpful. And then just one more on the de novos. With the Florida de novos maybe being pushed back a little bit. Is that changing how you're thinking about this full year de novo losses?

Yes. I mean the for facilities, if they're going to get pushed back or get pushed back by a relatively small amount of time, these are things where we might move it back by 4 weeks or 8 weeks. What you find is that, we have de novo losses associated with those facilities. To the extent that those get pushed back, the de novo losses are decreased slightly for the course of the year. At this point, I think we're sticking with the guidance that we've got related to de novo losses. But as we get towards February, where we hope we're going to have an Investor Day, we'll know a lot more about the business, we'll know a lot more, but timing of floor facilities. And to the extent there are any update to be given then we'll give them that.

Yes I would just add one last point on that is, obviously, we're timing our hiring and being very agile and being absolutely certain that we ensure we don't assume any cost any earlier than is absolutely necessary. So we're managing this very well.